Explore
Validate
Learn
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-573-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-573-C100, RRID:AB_2051117
- Product name
- c-erbB-2 (human) monoclonal antibody (MGR2)
- Antibody type
- Monoclonal
- Antigen
- Purified from natural sources
- Description
- Protein G affinity purified.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- MGR2
- Vial size
- 100 μg
- Storage
- +4°C
- Handling
- Do not freeze.
Submitted references Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides.
p185 HER2/neu epitope mapping with murine monoclonal antibodies.
Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.
Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, Pierotti MA, Pilotti S
Neuro-oncology 2010 Aug;12(8):776-89
Neuro-oncology 2010 Aug;12(8):776-89
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S, Tagliabue E
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Mar 15;15(6):2010-21
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Mar 15;15(6):2010-21
Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Ménard S
Cancer research 2005 Feb 1;65(3):1071-8
Cancer research 2005 Feb 1;65(3):1071-8
Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides.
Orlandi R, Ménard S, Colnaghi MI, Boyer CM, Felici F
European journal of immunology 1994 Nov;24(11):2868-73
European journal of immunology 1994 Nov;24(11):2868-73
p185 HER2/neu epitope mapping with murine monoclonal antibodies.
Centis F, Tagliabue E, Uppugunduri S, Pellegrini R, Martignone S, Mastroianni A, Ménard S, Colnaghi MI
Hybridoma 1992 Jun;11(3):267-76
Hybridoma 1992 Jun;11(3):267-76
Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.
Tagliabue E, Centis F, Campiglio M, Mastroianni A, Martignone S, Pellegrini R, Casalini P, Lanzi C, Ménard S, Colnaghi MI
International journal of cancer 1991 Apr 1;47(6):933-7
International journal of cancer 1991 Apr 1;47(6):933-7
No comments: Submit comment
No validations: Submit validation data